Individualized Treatment Strategy for Cutaneous Melanoma: Where Are We Now and Where Are We Going?

Zeng, Huihua; Liu, Fen; Zhou, Hairong; Zeng, Changchun

doi:10.3389/fonc.2021.775100

Cited by 7 publications

(7 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the clinician should be alerted that current immunohistochemical testing only identifies the V600E variant, and a more nuanced understanding of other BRAF mutational variants is worthy of additional molecular testing given their less active but clinically relevant activity to BRAF-targeted therapies. [99][100][101] Additional molecular testing of CKIT mutations may also be considered in rare cases within the small subset of patients who are BRAF wildtype and progress on or are ineligible for ICI therapy. 97 In patients with advanced melanoma harboring a BRAF mutation without contraindications to ICI, we advise the prioritization of combination immunotherapy over approved targeted agents in the first-line setting.…”

Section: Advanced Metastatic Diseasementioning

confidence: 99%

Managing Metastatic Melanoma in 2022: A Clinical Review

Switzer

Puzanov

Skitzki

et al. 2022

JCO Oncology Practice

133

View full text Add to dashboard Cite

Cutaneous melanoma remains the most lethal of the primary cutaneous neoplasms, and although the incidence of primary melanoma continues to rise, the mortality from metastatic disease remains unchanged, in part through advances in treatment. Major developments in immunomodulatory and targeted therapies have provided robust improvements in response and survival trends that have transformed the clinical management of patients with metastatic melanoma. Additional advances in immunologic and cancer cell biology have contributed to further optimization in (1) risk stratification, (2) prognostication, (3) treatment, (4) toxicity management, and (5) surveillance approaches for patients with an advanced melanoma diagnosis. In this review, we provide a comprehensive overview of the historical and future advances regarding the translational and clinical implications of advanced melanoma and share multidisciplinary recommendations to aid clinicians in the navigation of current treatment approaches for a variety of patient cohorts.

show abstract

Section: Advanced Metastatic Diseasementioning

confidence: 99%

Managing Metastatic Melanoma in 2022: A Clinical Review

Switzer

Puzanov

Skitzki

et al. 2022

JCO Oncology Practice

133

View full text Add to dashboard Cite

show abstract

“…In 2020, an estimated 325,000 new cases of melanoma were diagnosed all over the world and 57,000 people died from the disease [ 2 ]. Even with recent advancements in melanoma therapies—namely, immunotherapies such as ipilimumab, targeted therapies such as vemurafenib or combination therapies such as polychemotherapy, polyimmunotherapy, and biochemotherapy—the management of advanced melanoma is very challenging [ 3 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

Combined Radiomodifying Effect of Fucoidan from the Brown Alga Saccharina cichorioides and Pacificusoside D from the Starfish Solaster pacificus in the Model of 3D Melanoma Cells

Malyarenko

Usoltseva

et al. 2023

Biomolecules

View full text Add to dashboard Cite

Cancer is one of the main causes of human mortality worldwide. Despite the advances in the diagnostics, surgery, radiotherapy, and chemotherapy, the search for more effective treatment regimens and drug combinations are relevant. This work aimed to assess the radiomodifying effect and molecular mechanism of action of fucoidan from the brown alga Saccharina cichorioides (ScF) and product of its autohydrolysis (ScF_AH) in combination with pacificusoside D from the starfish Solaster pacificus (SpD) on the model of viability and invasion of three-dimension (3D) human melanoma cells SK-MEL-2. The cytotoxicity of ScF (IC50 JB6 Cl41 > 800 µg/mL; IC50 SK-MEL-2 = 685.7 µg/mL), ScF_AH (IC50 JB6 Cl41/SK-MEL-2 > 800 µg/mL), SpD (IC50 JB6 Cl41 = 22 µM; IC50 SK-MEL-2 = 5.5 µM), and X-ray (ID50 JB6 Cl41 = 11.7 Gy; ID50 SK-MEL-2 = 6.7 Gy) was determined using MTS assay. The efficiency of two-component treatment of 3D SK-MEL-2 cells was revealed for ScF in combination with SpD or X-ray but not for the combination of fucoidan derivative ScF_AH with SpD or X-ray. The pre-treatment of spheroids with ScF, followed by cell irradiation with X-ray and treatment with SpD (three-component treatment) at low non-toxic concentrations, led to significant inhibition of the spheroids’ viability and invasion and appeared to be the most effective therapeutic scheme for SK-MEL-2 cells. The molecular mechanism of radiomodifying effect of ScF with SpD was associated with the activation of the initiator and effector caspases, which in turn caused the DNA degradation in SK-MEL-2 cells as determined by the Western blotting and DNA comet assays. Thus, the combination of fucoidan from brown algae and triterpene glycoside from starfish with radiotherapy might contribute to the development of highly effective method for melanoma therapy.

show abstract

“…Cutaneous melanoma is the most prevalent etiology of skin cancer. In 2021, approximately 101,280 new melanoma cases were predicted in the United States (1,2). Currently, innovative approaches such as target therapies and immunotherapies have been introduced in clinical practice for the treatment of cutaneous melanoma (3).…”

Section: Introductionmentioning

confidence: 99%

“…More in detail, target therapies are based on the use of drugs targeting specific genetic alterations in candidate genes, blocking specific pathways implicated in the oncogenesis of melanoma (3). The most important is the MAP-Kinase (B-RAF/ MEK/ERK) pathway (1). Among immunotherapies, checkpoint inhibitors target specific receptors on T-lymphocytes, such as anti-CTL-A4, anti-PD-1/PDL-1, and anti-LAG-3.…”

Section: Introductionmentioning

confidence: 99%

Quality of Life Predictors in Patients With Melanoma: A Machine Learning Approach

et al. 2022

View full text Add to dashboard Cite

Health related quality of life (HRQoL) is an important recognized health outcome for cancer treatments, but also disease course with slower recovery and increased morbidity. These issues are of implication in melanoma, which maintains a risk of disease progression for many years after diagnosis. This study aimed to explore and weigh factors in the perception of the quality of life and possible relationships with demographic–clinical characteristics in people with melanoma via a machine learning approach. In this observational study, patients with melanoma, without metastatic disease, were recruited from January 2020 to December 2021 with a follow-up of at least one year. Demographic variables and clinics were collected, and the 12-Item Short-Form Health Survey (SF-12) was adopted as the physical and mental aspects of the Health-Related Quality of Life (HRQoL) measure. All the variables were processed in a random forest model to weigh at each node of each tree of this machine learning regression model, their actual weight in SF-12 score. We included 203 melanoma patients, mean aged 59.25 ± 15.1 years: 56 (27%) affecting the upper limbs and 147 (73%) affecting the trunk. The model of 142 patients with no missing value, generating 92 trees (MSE = 0.45, R2 of 0.78), reported that the lesion site was the most influencing variable on HRQoL based on the decrease in Gini impurity in variable weighing at each node intersection in forest generation. In this scenario, we built two distinct models for lesion sites and demonstrated that the variable that most influenced the quality of life in upper limb melanoma was lymphedema, while BMI was in the trunk. Given these results, random forest regressions could play a crucial role in the clinical and rehabilitation approach. The machine-learning model for detecting the HRQoL predictor in melanoma patients indicates that the experienced lymphedema and BMI may influence the HRQoL perception. This study suggests that the prevention and treatment of lymphedema and bodyweight reduction might improve the quality of life in melanoma.

show abstract

Individualized Treatment Strategy for Cutaneous Melanoma: Where Are We Now and Where Are We Going?

Cited by 7 publications

References 84 publications

Managing Metastatic Melanoma in 2022: A Clinical Review

Managing Metastatic Melanoma in 2022: A Clinical Review

Combined Radiomodifying Effect of Fucoidan from the Brown Alga Saccharina cichorioides and Pacificusoside D from the Starfish Solaster pacificus in the Model of 3D Melanoma Cells

Quality of Life Predictors in Patients With Melanoma: A Machine Learning Approach

Contact Info

Product

Resources

About